schliessen

Filtern

 

Bibliotheken

Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)

Aims/hypothesis We conducted an analysis of data collected during the Veterans Affairs Diabetes Trial (VADT) and the follow-up study (VADT-F) to determine whether intensive (INT) compared with standard (STD) glycaemic control during the VADT resulted in better long-term kidney outcomes. Methods VADT... Full description

Journal Title: Diabetologia 2017-11-03, Vol.61 (2), p.295-299
Main Author: Agrawal, Lily
Other Authors: Azad, Nasrin , Bahn, Gideon D , Ge, Ling , Reaven, Peter D , Hayward, Rodney A , Reda, Domenic J , Emanuele, Nicholas V
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Berlin/Heidelberg: Springer Berlin Heidelberg
ID: ISSN: 0012-186X
Link: https://www.ncbi.nlm.nih.gov/pubmed/29101421
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5747983
title: Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)
format: Article
creator:
  • Agrawal, Lily
  • Azad, Nasrin
  • Bahn, Gideon D
  • Ge, Ling
  • Reaven, Peter D
  • Hayward, Rodney A
  • Reda, Domenic J
  • Emanuele, Nicholas V
subjects:
  • Albumin
  • Analysis
  • Article
  • Blood Glucose - drug effects
  • Blood pressure
  • Chronic kidney failure
  • Clinical trials
  • Creatinine
  • Creatinine - urine
  • Data processing
  • Diabetes
  • Diabetes mellitus
  • Diabetes Mellitus, Type 2 - blood
  • Diabetes Mellitus, Type 2 - drug therapy
  • Diabetes therapy
  • Diabetic Retinopathy - drug therapy
  • Diabetic Retinopathy - metabolism
  • Epidermal growth factor receptors
  • Female
  • Follow-Up Studies
  • Glomerular Filtration Rate - drug effects
  • Glycated Hemoglobin A - metabolism
  • Human Physiology
  • Humans
  • Hypoglycemic Agents - therapeutic use
  • Insulin - therapeutic use
  • Intensive glycaemic control
  • Internal Medicine
  • Kidney - drug effects
  • Kidney - metabolism
  • Kidney - physiopathology
  • Kidney diseases
  • Kidney transplantation
  • Male
  • Medicine
  • Medicine & Public Health
  • Metabolic Diseases
  • Nephropathy
  • Renal outcomes
  • Serum Albumin, Human - urine
  • Short Communication
  • Treatment Outcome
  • Type 2 diabetes
  • Urine
  • Veterans
ispartof: Diabetologia, 2017-11-03, Vol.61 (2), p.295-299
description: Aims/hypothesis We conducted an analysis of data collected during the Veterans Affairs Diabetes Trial (VADT) and the follow-up study (VADT-F) to determine whether intensive (INT) compared with standard (STD) glycaemic control during the VADT resulted in better long-term kidney outcomes. Methods VADT randomly assigned 1791 veterans from 20 Veterans Affairs (VA) medical centres who had type 2 diabetes mellitus and a mean HbA 1c of 9.4 ± 2% (79.2 mmol/mol) at baseline to receive either INT or STD glucose control for a median of 5.6 years (randomisation December 2000 to May 2003; intervention ending in May 2008). After the trial, participants received routine care through their own physicians within the VA. This is an interim analysis of the VADT-F (June 2008 to December 2013). We collected data using VA and National databases and report renal outcomes based on serum creatinine, eGFR and urine albumin to creatinine ratio (ACR) in 1033 people who provided informed consent to participate in the VADT-F. Results By the end of the VADT-F, significantly more people who received INT treatment during the VADT maintained an eGFR >60 ml min −1 1.73 m −2 (OR 1.34 [95% CI 1.05, 1.71], p  = 0.02). This benefit was most evident in those who were classified as at moderate risk (INT vs STD, RR 1.3, p  = 0.03) or high risk (RR 2.3, p  = 0.04) of chronic kidney disease on the Kidney Disease Improving Global Outcomes (KDIGO-CKD) at the beginning of VADT. At the end of VADT-F, significantly more people from the INT group improved to a low KDIGO risk category (RR 6.1, p  = 0.002). During the VADT-F there were no significant differences between INT and STD for average HbA 1c , blood pressure or lipid levels. Conclusions/interpretation After just over 11 years of follow-up, there was a 34% greater odds of maintaining an eGFR of >60 ml min −1 1.73 m −2 and of improving the KDIGO category in individuals with type 2 diabetes who had received INT for a median of 5.6 years. VADT clinical trials.gov number: NCT 00032487.
language: eng
source:
identifier: ISSN: 0012-186X
fulltext: no_fulltext
issn:
  • 0012-186X
  • 1432-0428
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6452155
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5747983
sourceformatXML
sourcesystemPC
galeidA520815859
sourcerecordidA520815859
originalsourceidFETCH-LOGICAL-1607t-a98072abfb2101613f6a1de91500a154151dad2906432362b77cc00bce84f0710
addsrcrecordideNp9kkFv1DAQhSMEokvhB3BBlriUQ8rYie3kgrRqgSKtxGWpuFmOM966ytqLnRT13-NoS-lWgHJIZL_36c3kFcVrCqcUQL5PAJTxEqgs61pWJXtSLGhdsRJq1jwtFvN1SRvx_ah4kdI1AFS8Fs-LI9ZSoDWjiyKugt-UI8YtsWEYws9y2pFgifMj-uRukGyGW6Nx6wwxwY8xDCR4EtHr_DGNJmwxZTUZr5BcYgZpn8jSWu1iIudOd_kskXV0WX9yuTxfv3tZPLN6SPjq7n1cfPv0cX12Ua6-fv5ytlyVVIAcS902IJnubMdyWEErKzTtsaUcQFNeU0573bMWRJ64EqyT0hiAzmBTW5AUjosPe-5u6rbYG8zp9aB20W11vFVBO3V4492V2oQbxWUt26bKgIs9IOzyuC7igbf3OKrQKyakMoIz3eZUqEFz21W9YA1ltjKdbWQnMurkLksMPyZMo9q6ZHAYtMcwJUVbAS1rZcOy9O0j6XWYYl73rJKSA2uq6o9qowdUztuQRzAzVC05g4byhrdZdfoXVX76-YcGj9bl8wMD3RtMDClFtPcjU1Bz59S-cyp3Ts2dU3PgNw_3fO_4XbIskI-gxo16dHOdtBv-i2Z7Z8pQv8H4YBf_NP0CJmTwPQ
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1977502833
display
typearticle
titleLong-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)
creatorAgrawal, Lily ; Azad, Nasrin ; Bahn, Gideon D ; Ge, Ling ; Reaven, Peter D ; Hayward, Rodney A ; Reda, Domenic J ; Emanuele, Nicholas V
creatorcontribAgrawal, Lily ; Azad, Nasrin ; Bahn, Gideon D ; Ge, Ling ; Reaven, Peter D ; Hayward, Rodney A ; Reda, Domenic J ; Emanuele, Nicholas V ; VADT Study Group ; for the VADT Study Group
descriptionAims/hypothesis We conducted an analysis of data collected during the Veterans Affairs Diabetes Trial (VADT) and the follow-up study (VADT-F) to determine whether intensive (INT) compared with standard (STD) glycaemic control during the VADT resulted in better long-term kidney outcomes. Methods VADT randomly assigned 1791 veterans from 20 Veterans Affairs (VA) medical centres who had type 2 diabetes mellitus and a mean HbA 1c of 9.4 ± 2% (79.2 mmol/mol) at baseline to receive either INT or STD glucose control for a median of 5.6 years (randomisation December 2000 to May 2003; intervention ending in May 2008). After the trial, participants received routine care through their own physicians within the VA. This is an interim analysis of the VADT-F (June 2008 to December 2013). We collected data using VA and National databases and report renal outcomes based on serum creatinine, eGFR and urine albumin to creatinine ratio (ACR) in 1033 people who provided informed consent to participate in the VADT-F. Results By the end of the VADT-F, significantly more people who received INT treatment during the VADT maintained an eGFR >60 ml min −1 1.73 m −2 (OR 1.34 [95% CI 1.05, 1.71], p  = 0.02). This benefit was most evident in those who were classified as at moderate risk (INT vs STD, RR 1.3, p  = 0.03) or high risk (RR 2.3, p  = 0.04) of chronic kidney disease on the Kidney Disease Improving Global Outcomes (KDIGO-CKD) at the beginning of VADT. At the end of VADT-F, significantly more people from the INT group improved to a low KDIGO risk category (RR 6.1, p  = 0.002). During the VADT-F there were no significant differences between INT and STD for average HbA 1c , blood pressure or lipid levels. Conclusions/interpretation After just over 11 years of follow-up, there was a 34% greater odds of maintaining an eGFR of >60 ml min −1 1.73 m −2 and of improving the KDIGO category in individuals with type 2 diabetes who had received INT for a median of 5.6 years. VADT clinical trials.gov number: NCT 00032487.
identifier
0ISSN: 0012-186X
1EISSN: 1432-0428
2DOI: 10.1007/s00125-017-4473-2
3PMID: 29101421
languageeng
publisherBerlin/Heidelberg: Springer Berlin Heidelberg
subjectAlbumin ; Analysis ; Article ; Blood Glucose - drug effects ; Blood pressure ; Chronic kidney failure ; Clinical trials ; Creatinine ; Creatinine - urine ; Data processing ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes therapy ; Diabetic Retinopathy - drug therapy ; Diabetic Retinopathy - metabolism ; Epidermal growth factor receptors ; Female ; Follow-Up Studies ; Glomerular Filtration Rate - drug effects ; Glycated Hemoglobin A - metabolism ; Human Physiology ; Humans ; Hypoglycemic Agents - therapeutic use ; Insulin - therapeutic use ; Intensive glycaemic control ; Internal Medicine ; Kidney - drug effects ; Kidney - metabolism ; Kidney - physiopathology ; Kidney diseases ; Kidney transplantation ; Male ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Nephropathy ; Renal outcomes ; Serum Albumin, Human - urine ; Short Communication ; Treatment Outcome ; Type 2 diabetes ; Urine ; Veterans
ispartofDiabetologia, 2017-11-03, Vol.61 (2), p.295-299
rights
0This is a U.S. government work and its text is not subject to copyright protection in the United States; however, its text may be subject to foreign copyright protection 2017
1COPYRIGHT 2018 Springer
2Diabetologia is a copyright of Springer, (2017). All Rights Reserved.
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1607t-a98072abfb2101613f6a1de91500a154151dad2906432362b77cc00bce84f0710
citesFETCH-LOGICAL-1607t-a98072abfb2101613f6a1de91500a154151dad2906432362b77cc00bce84f0710
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29101421$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Agrawal, Lily
1Azad, Nasrin
2Bahn, Gideon D
3Ge, Ling
4Reaven, Peter D
5Hayward, Rodney A
6Reda, Domenic J
7Emanuele, Nicholas V
8VADT Study Group
9for the VADT Study Group
title
0Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)
1Diabetologia
addtitle
0Diabetologia
1Diabetologia
descriptionAims/hypothesis We conducted an analysis of data collected during the Veterans Affairs Diabetes Trial (VADT) and the follow-up study (VADT-F) to determine whether intensive (INT) compared with standard (STD) glycaemic control during the VADT resulted in better long-term kidney outcomes. Methods VADT randomly assigned 1791 veterans from 20 Veterans Affairs (VA) medical centres who had type 2 diabetes mellitus and a mean HbA 1c of 9.4 ± 2% (79.2 mmol/mol) at baseline to receive either INT or STD glucose control for a median of 5.6 years (randomisation December 2000 to May 2003; intervention ending in May 2008). After the trial, participants received routine care through their own physicians within the VA. This is an interim analysis of the VADT-F (June 2008 to December 2013). We collected data using VA and National databases and report renal outcomes based on serum creatinine, eGFR and urine albumin to creatinine ratio (ACR) in 1033 people who provided informed consent to participate in the VADT-F. Results By the end of the VADT-F, significantly more people who received INT treatment during the VADT maintained an eGFR >60 ml min −1 1.73 m −2 (OR 1.34 [95% CI 1.05, 1.71], p  = 0.02). This benefit was most evident in those who were classified as at moderate risk (INT vs STD, RR 1.3, p  = 0.03) or high risk (RR 2.3, p  = 0.04) of chronic kidney disease on the Kidney Disease Improving Global Outcomes (KDIGO-CKD) at the beginning of VADT. At the end of VADT-F, significantly more people from the INT group improved to a low KDIGO risk category (RR 6.1, p  = 0.002). During the VADT-F there were no significant differences between INT and STD for average HbA 1c , blood pressure or lipid levels. Conclusions/interpretation After just over 11 years of follow-up, there was a 34% greater odds of maintaining an eGFR of >60 ml min −1 1.73 m −2 and of improving the KDIGO category in individuals with type 2 diabetes who had received INT for a median of 5.6 years. VADT clinical trials.gov number: NCT 00032487.
subject
0Albumin
1Analysis
2Article
3Blood Glucose - drug effects
4Blood pressure
5Chronic kidney failure
6Clinical trials
7Creatinine
8Creatinine - urine
9Data processing
10Diabetes
11Diabetes mellitus
12Diabetes Mellitus, Type 2 - blood
13Diabetes Mellitus, Type 2 - drug therapy
14Diabetes therapy
15Diabetic Retinopathy - drug therapy
16Diabetic Retinopathy - metabolism
17Epidermal growth factor receptors
18Female
19Follow-Up Studies
20Glomerular Filtration Rate - drug effects
21Glycated Hemoglobin A - metabolism
22Human Physiology
23Humans
24Hypoglycemic Agents - therapeutic use
25Insulin - therapeutic use
26Intensive glycaemic control
27Internal Medicine
28Kidney - drug effects
29Kidney - metabolism
30Kidney - physiopathology
31Kidney diseases
32Kidney transplantation
33Male
34Medicine
35Medicine & Public Health
36Metabolic Diseases
37Nephropathy
38Renal outcomes
39Serum Albumin, Human - urine
40Short Communication
41Treatment Outcome
42Type 2 diabetes
43Urine
44Veterans
issn
00012-186X
11432-0428
fulltextfalse
rsrctypearticle
creationdate2017
recordtypearticle
recordideNp9kkFv1DAQhSMEokvhB3BBlriUQ8rYie3kgrRqgSKtxGWpuFmOM966ytqLnRT13-NoS-lWgHJIZL_36c3kFcVrCqcUQL5PAJTxEqgs61pWJXtSLGhdsRJq1jwtFvN1SRvx_ah4kdI1AFS8Fs-LI9ZSoDWjiyKugt-UI8YtsWEYws9y2pFgifMj-uRukGyGW6Nx6wwxwY8xDCR4EtHr_DGNJmwxZTUZr5BcYgZpn8jSWu1iIudOd_kskXV0WX9yuTxfv3tZPLN6SPjq7n1cfPv0cX12Ua6-fv5ytlyVVIAcS902IJnubMdyWEErKzTtsaUcQFNeU0573bMWRJ64EqyT0hiAzmBTW5AUjosPe-5u6rbYG8zp9aB20W11vFVBO3V4492V2oQbxWUt26bKgIs9IOzyuC7igbf3OKrQKyakMoIz3eZUqEFz21W9YA1ltjKdbWQnMurkLksMPyZMo9q6ZHAYtMcwJUVbAS1rZcOy9O0j6XWYYl73rJKSA2uq6o9qowdUztuQRzAzVC05g4byhrdZdfoXVX76-YcGj9bl8wMD3RtMDClFtPcjU1Bz59S-cyp3Ts2dU3PgNw_3fO_4XbIskI-gxo16dHOdtBv-i2Z7Z8pQv8H4YBf_NP0CJmTwPQ
startdate20171103
enddate20171103
creator
0Agrawal, Lily
1Azad, Nasrin
2Bahn, Gideon D
3Ge, Ling
4Reaven, Peter D
5Hayward, Rodney A
6Reda, Domenic J
7Emanuele, Nicholas V
general
0Springer Berlin Heidelberg
1Springer
2Springer Nature B.V
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
93V.
107T5
117X7
127XB
1388E
148AO
158C1
168FI
178FJ
188FK
19ABUWG
20BENPR
21FYUFA
22GHDGH
23H94
24K9.
25M0S
26M1P
27PQEST
28PQQKQ
29PQUKI
30PRINS
317X8
32BOBZL
33CLFQK
345PM
sort
creationdate20171103
titleLong-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)
authorAgrawal, Lily ; Azad, Nasrin ; Bahn, Gideon D ; Ge, Ling ; Reaven, Peter D ; Hayward, Rodney A ; Reda, Domenic J ; Emanuele, Nicholas V
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1607t-a98072abfb2101613f6a1de91500a154151dad2906432362b77cc00bce84f0710
rsrctypearticles
prefilterarticles
languageeng
creationdate2017
topic
0Albumin
1Analysis
2Article
3Blood Glucose - drug effects
4Blood pressure
5Chronic kidney failure
6Clinical trials
7Creatinine
8Creatinine - urine
9Data processing
10Diabetes
11Diabetes mellitus
12Diabetes Mellitus, Type 2 - blood
13Diabetes Mellitus, Type 2 - drug therapy
14Diabetes therapy
15Diabetic Retinopathy - drug therapy
16Diabetic Retinopathy - metabolism
17Epidermal growth factor receptors
18Female
19Follow-Up Studies
20Glomerular Filtration Rate - drug effects
21Glycated Hemoglobin A - metabolism
22Human Physiology
23Humans
24Hypoglycemic Agents - therapeutic use
25Insulin - therapeutic use
26Intensive glycaemic control
27Internal Medicine
28Kidney - drug effects
29Kidney - metabolism
30Kidney - physiopathology
31Kidney diseases
32Kidney transplantation
33Male
34Medicine
35Medicine & Public Health
36Metabolic Diseases
37Nephropathy
38Renal outcomes
39Serum Albumin, Human - urine
40Short Communication
41Treatment Outcome
42Type 2 diabetes
43Urine
44Veterans
toplevelpeer_reviewed
creatorcontrib
0Agrawal, Lily
1Azad, Nasrin
2Bahn, Gideon D
3Ge, Ling
4Reaven, Peter D
5Hayward, Rodney A
6Reda, Domenic J
7Emanuele, Nicholas V
8VADT Study Group
9for the VADT Study Group
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8ProQuest Central (Corporate)
9Immunology Abstracts
10Health & Medical Collection
11ProQuest Central (purchase pre-March 2016)
12Medical Database (Alumni Edition)
13ProQuest Pharma Collection
14Public Health Database
15Hospital Premium Collection
16Hospital Premium Collection (Alumni Edition)
17ProQuest Central (Alumni) (purchase pre-March 2016)
18ProQuest Central (Alumni Edition)
19ProQuest Central
20Health Research Premium Collection
21Health Research Premium Collection (Alumni)
22AIDS and Cancer Research Abstracts
23ProQuest Health & Medical Complete (Alumni)
24Health & Medical Collection (Alumni Edition)
25Medical Database
26ProQuest One Academic Eastern Edition
27ProQuest One Academic
28ProQuest One Academic UKI Edition
29ProQuest Central China
30MEDLINE - Academic
31OpenAIRE (Open Access)
32OpenAIRE
33PubMed Central (Full Participant titles)
jtitleDiabetologia
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Agrawal, Lily
1Azad, Nasrin
2Bahn, Gideon D
3Ge, Ling
4Reaven, Peter D
5Hayward, Rodney A
6Reda, Domenic J
7Emanuele, Nicholas V
aucorp
0VADT Study Group
1for the VADT Study Group
formatjournal
genrearticle
ristypeJOUR
atitleLong-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)
jtitleDiabetologia
stitleDiabetologia
addtitleDiabetologia
date2017-11-03
risdate2017
volume61
issue2
spage295
epage299
pages295-299
issn0012-186X
eissn1432-0428
abstractAims/hypothesis We conducted an analysis of data collected during the Veterans Affairs Diabetes Trial (VADT) and the follow-up study (VADT-F) to determine whether intensive (INT) compared with standard (STD) glycaemic control during the VADT resulted in better long-term kidney outcomes. Methods VADT randomly assigned 1791 veterans from 20 Veterans Affairs (VA) medical centres who had type 2 diabetes mellitus and a mean HbA 1c of 9.4 ± 2% (79.2 mmol/mol) at baseline to receive either INT or STD glucose control for a median of 5.6 years (randomisation December 2000 to May 2003; intervention ending in May 2008). After the trial, participants received routine care through their own physicians within the VA. This is an interim analysis of the VADT-F (June 2008 to December 2013). We collected data using VA and National databases and report renal outcomes based on serum creatinine, eGFR and urine albumin to creatinine ratio (ACR) in 1033 people who provided informed consent to participate in the VADT-F. Results By the end of the VADT-F, significantly more people who received INT treatment during the VADT maintained an eGFR >60 ml min −1 1.73 m −2 (OR 1.34 [95% CI 1.05, 1.71], p  = 0.02). This benefit was most evident in those who were classified as at moderate risk (INT vs STD, RR 1.3, p  = 0.03) or high risk (RR 2.3, p  = 0.04) of chronic kidney disease on the Kidney Disease Improving Global Outcomes (KDIGO-CKD) at the beginning of VADT. At the end of VADT-F, significantly more people from the INT group improved to a low KDIGO risk category (RR 6.1, p  = 0.002). During the VADT-F there were no significant differences between INT and STD for average HbA 1c , blood pressure or lipid levels. Conclusions/interpretation After just over 11 years of follow-up, there was a 34% greater odds of maintaining an eGFR of >60 ml min −1 1.73 m −2 and of improving the KDIGO category in individuals with type 2 diabetes who had received INT for a median of 5.6 years. VADT clinical trials.gov number: NCT 00032487.
copBerlin/Heidelberg
pubSpringer Berlin Heidelberg
pmid29101421
doi10.1007/s00125-017-4473-2
oafree_for_read